Dernières nouvelles pour Palladyne AI (NASDAQ:PDYN) Stock

Palladyne AI

Palladyne AI Corp is a software company focused on autonomy for robotic systems and solutions. Its artificial intelligence and machine learning software seeks to revolutionize the capabilities of robots, enabling them to observe, learn, reason, and act in structured and unstructured environments. AI and ML software platform of the company empowers robots to perceive variations or changes in the real-world environment, enabling them to autonomously maneuver and manipulate objects accurately in response. Palladyne AI software has wide application, including in industries such as automotive, aviation, construction, defense, general manufacturing, infrastructure inspection, logistics and warehousing.

Palladyne AI Corp

Options

Markets

Trading Ideas

SentinelOne Option Alert: Aug 15 $25 Calls Sweep (38) near the Ask: 1000 @ $0.35 vs 0 OI; Earnings 8/26 After Close [est] Ref=$20.845

A pseudonymous trader that accurately predicted the local bottom on major cryptocurrencies in April is now warning that August may see a <a href="https://www.benzinga.com/money/bitcoin-price-prediction">local top for the crypto market</a>.
On July 18, Nachi <a href="https://x.com/alphawifhat/status/1946276742534135848">revisited</a> his April call, emphasizing that the ideal time to go aggressive was then, not now. 
He warns that the market is in a late bullish stage, and traders should be cautious with leverage going forward.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Current Price</td>
<td>Price As Of April 22</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$117,917.54</td>
<td>$90,721</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,783.80</td>
<td>$1,693</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$195.49</td>
<td>$144</td>
</tr>
<tr>
<td>Sui</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SUI</a>)</td>
<td>$3.99</td>
<td>$2.46</td>
</tr>
<tr>
<td>Hyperliquid</td>
<td>(CRYPTO: HYPE)</td>
<td>$46.11</td>
<td>$18.83</td>
</tr>
</tbody>
</table>
</figure>
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46515951/bitcoin-holds-steady-ethereum-solana-dogecoin-lead-monday-rally">Bitcoin Holds Steady, Ethereum, Solana, Dogecoin Lead Monday Rally</a>
What's Next: Nachi's original thesis pointed to April–August 2025 as the most bullish window for crypto, fuelled by easing rates, cooling inflation, and improving sentiment. 
However, he now believes the top could form in August, especially if no new bullish catalysts emerge.
He cautioned: "The market tops when liquidity and bullish news top out, and that could happen by the end of summer."
Nachi also observed that "Dino coins" (old altcoins) pumping hard is a classic sign of frothy market behaviour, a typical signal that things may be peaking.
Still, he continues to hold most of his long positions and expects consolidation or pullback before another leg higher. For Bitcoin to hit $150,000 by August, he said, "something really wild needs to happen."
Nachi had added that if Trump intensifies tariffs or macro conditions shift unexpectedly, that could delay or extend the top.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46508890/trump-signs-genius-act-ending-biden-era-crypto-probes-and-backing-industry-titans">Trump Signs GENIUS Act, Ending Biden-Era Crypto Probes and Backing Industry Titans</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$ETH

$SOL

$SUI

Trader Who Called Bitcoin, Ethereum, Solana Bottom In April Now Warns Local Top Likely In August

WIIM

RYAAY

Ryanair shares are trading higher following Q1 financial results.

Biogen Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina&#8217;s Research <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Triangle Park (RTP)</a>.
Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46515310/biogen-announces-2-billion-manufacturing-investment-in-north-carolinas-research-triangle-park-in-c" rel="noreferrer noopener">late-stage clinical pipeline</a>.
In the next few years, Biogen plans to continue investing in multiple modalities and factories across the company&#8217;s two campuses in RTP.
These investments will include further expanding the antisense oligonucleotide (ASO) capabilities and infrastructure, establishing clinical and commercial multi-platform fill finish capabilities, and modernizing manufacturing technologies and controls through further advanced automation and artificial intelligence.
Also Read: <a href="https://www.benzinga.com/markets/large-cap/25/06/46102291/biogen-ionis-partnered-drug-shows-benefit-in-children-with-spinal-muscular-atrophy-previously-treated-with-novartis-zolgensma" target="_blank" rel="noreferrer noopener">Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis&#8217; Zolgensma</a>
&#8220;Our manufacturing footprint in the United States has played a critical role in Biogen&#8217;s history and success and in advancing the treatments &#8230; With this investment, we will modernize and expand our manufacturing capability to enable our pipeline and provide resilient patient supply&#8230;,&#8221; said Nicole Murphy, head of pharmaceutical operations and technology at Biogen.
North Carolina&#8217;s RTP is home to Biogen&#8217;s largest manufacturing footprint.
As the state&#8217;s largest biotechnology employer and one of the top five biopharmaceutical employers, Biogen employs over 1,500 manufacturing and technical employees and more than 400 skilled contractors across its Wake County and Durham County campuses.
More than 90% of commercial medicines produced by Biogen have manufacturing and quality control testing in the U.S.
Earlier in May, U.S. President&nbsp;Donald Trump&#8217;s signed an executive order to promote prescription drug manufacturing in the U.S., streamlining the path for companies to build new production sites as potential tariffs on&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">imported medicines loom</a>.
The White House wants facilities to come on board at a faster rate. It&nbsp;<a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">estimates</a> that it can currently take five to 10 years to build new pharmaceutical manufacturing capacity, which it calls &#8220;unacceptable from a national-security standpoint."
<a href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" target="_blank" rel="noreferrer noopener">Amid tariff uncertainty</a>, many drug companies are investing to boost production within the U.S.:
Eli Lilly And Co doubled <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">domestic medicine production</a>.
Thermo Fisher Scientific Inc. announced it would invest an additional $2 billion in the U.S. over <a href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" target="_blank" rel="noreferrer noopener">the next four years</a>.
Medtech firm Becton, Dickinson, and Company also announced its intention to invest $2.5 billion in U.S. manufacturing capacity <a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">over the next five years</a>.
Regeneron Pharmaceuticals, Inc. seeks to nearly double its manufacturing capacity through a new agreement with <a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" target="_blank" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>.
Novartis AG unveiled a $23 billion investment plan to expand in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" target="_blank" rel="noreferrer noopener">over the next five years</a>.
Johnson &amp; Johnson plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.
Roche Holdings AG announced that it will invest $50 billion in the U.S. over <a href="https://www.benzinga.com/topic/pharmaceuticals" target="_blank" rel="noreferrer noopener">the next five years.</a>
Bristol-Myers Squibb &amp; Co.&#8217;s Christopher Boerner, chair and chief executive officer, <a href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" target="_blank" rel="noreferrer noopener">shared</a> plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years.
Sanofi SA announced it will invest at least $20 billion in the <a href="https://www.benzinga.com/25/05/45419235/sanofi-joins-other-big-pharma-to-navigate-potential-tariff-impact-with-at-least-20-billion-in-investments-through-2030" target="_blank" rel="noreferrer noopener">U.S. through 2030</a>. The bulk of the spending will go to R&amp;D and U.S. manufacturing.
BIIB Price Action: BIIB stock is down 1.46% at $123.17 at publication on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46512836/elon-musks-tesla-announces-3-million-model-3-units-sold-worldwide" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Tesla Announces 3 Million Model 3 Units Sold Worldwide</a> Photo Courtesy: PeopleImages.com, Yuri A on Shutterstock</li>
</ul>

Biotech

Large Cap

Health Care

Movers

General

BIIB

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Gold and silver are trading higher amid US dollar weakness.

D-Wave Quantum Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) shares are trading higher Monday after the company announced results of a new study that highlights the potential for quantum optimization to create <a href="https://www.benzinga.com/node/46514740">value across industries</a>.
What To Know: According to the study, 27% of surveyed business leaders expect a return on investment exceeding $5 million within the first year of adopting quantum optimization. Another 46% anticipate ROI between $1 million and $5 million. The findings are based on a survey of 400 business leaders across North America, Europe and Asia Pacific conducted by Wakefield Research in collaboration with D-Wave.
The study also found that 81% of respondents believe their organizations have reached the limits of classical computing when it comes to optimization solutions. As a result, 53% plan to integrate quantum computing into their workflows, and another 27% are considering integrating quantum solutions.
D-Wave said the findings underscore the growing recognition of quantum computing&#8217;s real-world potential, particularly in industries like supply chain and logistics, manufacturing, inventory planning and R&amp;D. Among respondents most familiar with the technology, 73% said they expect quantum optimization to be very helpful in addressing operational challenges, and nearly a quarter of those respondents described it as a "game changer."
The company said the push for better optimization is driven by the need to improve efficiency, reduce costs and drive innovation. Common obstacles include outdated technology, budget constraints, reliance on classical systems and staffing shortages.
D-Wave CEO Alan Baratz said the results demonstrate strong momentum toward enterprise adoption of quantum solutions.
 "This survey reflects the rapidly growing interest in applying quantum to complex optimization use cases, with business leaders unequivocally recognizing the substantial potential ROI of doing so," Baratz said.
Related Link: <a href="https://www.benzinga.com/markets/tech/25/07/46518219/alphabet-set-for-strong-q2-earnings-but-analysts-warn-ai-search-remains-googles-war-to-lose">Alphabet Set For Strong Q2 Earnings — But Analysts Warn: &#8216;AI Search Remains Google&#8217;s War To Lose&#8217;</a>
QBTS Price Action: At the time of publication Monday, D-Wave shares were up 1.89% at $19.25, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. The stock reached an all-time high of $20.56 in Monday&#8217;s session before pulling back.
Image via Shutterstock

QBTS

D-Wave Quantum Stock Is Trading Higher Monday: What's Going On?

GOOG

GOOGL

Alphabet shares are trading higher after Morgan Stanley maintained an overweight rating and raised its price target from $185 to $205.

<a href="https://www.calcalistech.com/ctechnews/article/kfqzwg5wr">https://www.calcalistech.com/ctechnews/article/kfqzwg5wr</a>

PANW

'Is Palo Alto Networks eyeing a SentinelOne takeover?'- CTech

QCOM

Qualcomm shares are trading higher after UBS maintained a neutral rating but raised its price target from $145 to $165.

<a href="https://www.cnn.com/2025/07/21/food/pepsi-prebiotic-soda-launch">https://www.cnn.com/2025/07/21/food/pepsi-prebiotic-soda-launch</a>

'Pepsi is betting a popular health trend can get more people to drink its soda'- CNN

Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Braket now offers customers access to IQM's newest <a href="https://www.benzinga.com/topic/amazon" target="_blank" rel="noreferrer noopener">quantum processing unit</a> (QPU), Emerald.
Emerald is a 54-qubit superconducting device with higher gate fidelity and full square lattice connectivity.
By adding Emerald to its platform, Amazon Braket expands its quantum hardware lineup, allowing users to choose between IQM's 20-qubit Garnet and the more advanced 54-qubit Emerald—<a target="_blank" href="https://aws.amazon.com/blogs/quantum-computing/amazon-braket-launches-new-54-qubit-superconducting-quantum-processor-from-iqm/" rel="noreferrer noopener">both available in</a> the Europe (Stockholm) Region.
This expansion supports researchers and developers in experimenting across multiple quantum systems, a critical step in advancing quantum algorithm development for complex challenges in finance, energy, pharma, and logistics.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/07/46252872/why-amazon-lags-its-peers-in-2025" target="_blank" rel="noreferrer noopener">Why Amazon Lags Its Peers In 2025</a>
<h2 class="wp-block-heading">Flexible Access And High-Performance Specs</h2>
Customers worldwide can run programs on-demand or reserve dedicated capacity on Emerald through Braket Direct. They offer flexible pricing options and priority execution for hybrid quantum-classical algorithms.
Emerald's Crystal 54 architecture uses superconducting transmon qubits arranged in a square lattice with tunable couplers, enabling efficient algorithm mapping and supporting native surface-code error correction—a key feature for future fault-tolerant quantum computing. The QPU supports flexible single- and two-qubit gate operations with high fidelities—99.93% for single-qubit and 99.5% for two-qubit gates.
Braket offers a unified programming interface, supporting the Braket SDK as well as other frameworks like Qiskit, Pennylane, and Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CUDA-Q. This makes it easy for users to build, test, and run quantum programs on Emerald.
<h2 class="wp-block-heading">AWS Pushes Ahead With Ocelot Prototype Chip</h2>
In February, Amazon Web Services (AWS) has advanced its <a href="https://www.benzinga.com/tech/25/02/44019698/amazon-unveils-ocelot-quantum-chip-after-microsoft-aims-to-slash-error-correction-costs-by-90" target="_blank" rel="noreferrer noopener">quantum computing efforts</a> by introducing Ocelot, a prototype quantum chip designed to reduce the cost of quantum error correction by up to 90%. 
Developed at the AWS Center for Quantum Computing at Caltech, Ocelot integrates cat qubit technology and scalable error correction components using semiconductor manufacturing techniques—highlighting AWS's focus on building commercially viable quantum hardware.
AWS aims to replicate its success in scaling cloud chips like Graviton by investing long-term in quantum R&amp;D. Ocelot represents a foundational step in AWS's strategy to develop secure, scalable quantum systems that can support future commercial applications.
<h2 class="wp-block-heading">Big Tech Accelerates the Quantum Race</h2>
Meanwhile, Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has accelerated its quantum roadmap by unveiling the Majorana 1 chip, a key milestone in its goal to scale quantum computing to one million qubits. The chip's development, supported by DARPA, leverages topological quantum materials to power artificial intelligence and high-performance computing breakthroughs.
Alphabet's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google is also advancing rapidly, with its Willow chip introduced last December. Willow focuses on exponential error reduction as qubit counts increase, bringing Google closer to launching commercial quantum applications within the next five years.
Nvidia has entered the space through a collaboration with Quantum AI. It aims to support quantum hardware development by combining its strengths in GPU acceleration with emerging quantum systems.
These corporate investments underscore the growing race to commercialize quantum computing.
Boston Consulting Group projects the global quantum computing market will generate $450 billion to $850 billion in economic value by 2040, supporting a $90 billion to $170 billion opportunity for hardware and software providers.
Price Action:&nbsp;AMZN stock is up 1.04% at $228.48 at last check Monday.
Read Next
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/07/46488931/comcast-hikes-peacock-prices-again-will-you-pay-11-a-month-for-ads" target="_blank" rel="noreferrer noopener">Comcast Hikes Peacock Prices Again: Will You Pay $11 A Month For Ads?</a></li>
</ul>
Image: Shutterstock

Tech

AMZN

MSFT

NVDA

Amazon Ups Quantum Game With New 54-Qubit QPU, Eyes Commercial Future

NEW YORK, NY, July 21, 2025 (GLOBE NEWSWIRE) -- Mercurity Fintech Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) ("Mercurity" or the "Company"), a leading innovator in digital asset treasury and blockchain-enabled financial infrastructure, today announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of its ordinary shares (or pre-funded warrants to purchase ordinary shares) and warrants to purchase ordinary shares in a registered direct offering. The offering is intended to support the Company's crypto treasury strategy and its continued development of on-chain financial tools.
Participants in this financing include LTP, Syntax Capital, OGBC Group, and Blockstone Capital, investment and financial services firms operating primarily in the digital assets and blockchain sector.
Under the terms of the agreements, the Company will issue 12,485,715 ordinary shares and 12,485,715 warrants in a registered direct offering. The effective offering price for each ordinary share is $3.50. The warrants will have an exercise price of $3.50 per share and a term of five years. The offering is expected to close on or about July 22, 2025, subject to customary closing conditions.

Offerings

Mercurity Fintech Reveals Pricing Of Registered Direct Offering Of $43.70M For Crypto Treasury Strategy

Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) shares gained on Monday after the company reported stronger-than-expected second-quarter results on Friday, surpassing analyst consensus estimates for both adjusted earnings per share and revenue.
The robust performance has prompted leading Wall Street analysts, including those from JP Morgan and Goldman Sachs, to re-rate the stock and raise their price forecasts, citing strong fundamentals, increased trading activity, and strategic growth initiatives, including the upcoming launch of Bitcoin and Ethereum trading services.
On Friday, Charles Schwab <a target="_blank" href="https://www.benzinga.com/markets/equities/25/07/46494057/schwabs-q2-revenue-rockets-25-1-million-new-accounts-added" rel="noreferrer noopener">reported second-quarter</a> adjusted earnings per share of $1.14, exceeding the analyst consensus estimate of $1.07. Quarterly sales reached $5.851 billion, a 25% year-over-year (Y/Y) increase, outpacing the Street&#8217;s projection of $5.651 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46500914/charles-schwab-to-launch-bitcoin-ethereum-trading-services" rel="noreferrer noopener">Charles Schwab To Launch Bitcoin, Ethereum Trading Services (CORRECTED)</a>
The company concluded the second quarter with $32.2 billion in cash and equivalents, while deposits stood at $233.1 billion, an 8% year-over-year decrease.
<h2 class="wp-block-heading">JP Morgan&#8217;s Perspective</h2>
JP Morgan analyst Kenneth B. Worthington <a target="_blank" href="https://www.benzinga.com/quote/SCHW/analyst-ratings" rel="noreferrer noopener">maintained an Overweight rating</a> on Charles Schwab, raising his price forecast from $100 to $117.
Worthington highlighted Schwab&#8217;s strong second-quarter performance, driven by better-than-expected net interest income (NII) and elevated trading activity amidst market volatility.
He noted that Schwab reported $5.9 billion in net revenue and a 50.1% adjusted pre-tax margin, exceeding projections. Trading revenue reached $952 million, an increase from both the previous quarter and year, with daily average trades climbing to 7.6 million. Worthington attributed NII tailwinds to reduced short-term debt and increased securities lending.
The analyst also viewed Schwab&#8217;s $80 billion in net new assets (NNA) as solid, pointing to an encouraging 4.9% annualized growth rate exiting the quarter. Contributions from legacy Ameritrade clients notably improved, with NNA from that segment more than doubling year over year.
Despite a slight quarter-over-quarter dip in interest-earning assets, Worthington anticipates growth will resume in the second half of 2025 as Schwab continues to reduce bank supplemental funding. He observed that client transactional sweep cash increased to $412 billion in June, signaling stable client engagement.
Worthington welcomed Schwab&#8217;s updated 2025 outlook, which raised revenue growth to 19% and projected $2.60 in adjusted EPS, while acknowledging that anticipated Fed rate cuts may pressure net interest margins. Nevertheless, he noted that the business momentum and financial flexibility position Schwab favorably for 2026, even as shares approach all-time highs. For fiscal 2025, Worthington projected net revenue of $23.5 billion and adjusted EPS of $4.62.
<h2 class="wp-block-heading">Goldman Sachs&#8217; Perspective</h2>
Goldman Sachs analyst Alexander Blostein reiterated a Buy rating on Charles Schwab, increasing his price forecast from $103 to $110. Blostein raised his 2025-2027 EPS estimates for Schwab to $4.69, $5.30, and $6.52, respectively, citing stronger-than-expected NII and disciplined expense management that drove operating margin upside. His updated projections now average approximately 4% above the Visible Alpha consensus.
Despite Schwab&#8217;s 30% year-to-date stock outperformance, Blostein noted further upside potential. He highlighted accelerating EPS growth supported by multiple factors: growing transactional cash balances, reduced supplemental borrowing, and renewed balance sheet expansion by the fourth quarter of 2025. The analyst also emphasized Schwab&#8217;s recent interest rate hedging efforts, which have decreased the firm&#8217;s sensitivity to declining short-term rates.
He noted that new product rollouts, such as a crypto trading platform and expanded alternatives offerings, also factored into the positive outlook. Blostein pointed out that these initiatives and the ongoing integration of legacy Ameritrade clients are expected to boost organic NNA growth into the company&#8217;s long-term 5-7% target range.
Following second-quarter&#8217;s 4.9% annualized core organic growth rate in June, the analyst expressed confidence in Schwab&#8217;s ability to maintain this trajectory. He also raised the full-year 2025 NII estimates, factoring in June&#8217;s $412 billion transactional cash and continued funding paydowns.
Looking ahead, Blostein expects Schwab&#8217;s net interest margin (NIM) to expand meaningfully, modeling 270 bps in 2025, 283 bps in 2026, and 306 bps in 2027. The analyst noted Schwab is well-positioned to benefit from securities reinvestment and a growing PAL loan portfolio, which rose 41% Y/Y.
Additionally, Blostein noted capital return as another key catalyst. With Schwab increasing its Tier 1 leverage ratio to 7.2% and repurchasing $350 million in stock in June, the analyst expects buybacks to accelerate as earnings grow and accumulated other comprehensive income (AOCI) improves.
Overall, he maintained a bullish view, projecting Schwab to deliver a 25% EPS CAGR through 2027 and pointing to the firm&#8217;s solid fundamentals, expanding offerings, and improving capital flexibility as strong long-term investment drivers.
Blostein projected fiscal 2025 net revenue of $23.5 billion (prior $23.4 billion) and adjusted EPS of $4.69 (prior $4.61).
SCHW Price Action: Charles Schwab shares were trading higher by 1.08% to $96.84 at the time of publication Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46490333/amex-q2-card-member-spending-hits-record-card-fees-soar" target="_blank" rel="noreferrer noopener">Amex Q2 Card Member Spending Hits Record, Card Fees Soar</a></li>
</ul>
Image via Shutterstock

Price Target

Reiteration

Analyst Ratings

SCHW

Charles Schwab's Crypto Plans Add Fuel To Post-Earnings Rally

BTOG

BTOG stock has given up its prior gain. Bit Origin shares were trading higher after the company announced it has purchased approximately 40.5 million units of Dogecoin.

Fundstrat's Head of Research Tom Lee on Monday reiterated his long-term bullish view on Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), saying the asset could surpass $1 million per coin <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46486386/tom-lee-says-michael-saylor-led-strategys-35x-surge-wasnt-just-bitcoin-treasury-moves-far-more-significant-than-token-price-gain">within the next few years</a>.
What Happened: In an <a href="https://www.youtube.com/watch?v=KR8EZo5IesE">interview</a> with CNBC, Lee grounded the projection in the thesis that Bitcoin continues to gain recognition as "digital gold" and should be valued accordingly at approximately 25% of gold's total market capitalization.
"If Bitcoin is digital gold, it should be worth over a million per coin, and it could happen in the next few years," Lee said.
He emphasized that the cryptocurrency market has evolved well beyond speculative trading. 
According to Lee, increasing interest from institutional investors and favorable regulatory developments, like the U.S. GENIUS Act, are laying the groundwork for continued adoption. 
These conditions, he noted, strengthen Bitcoin's position as a macro asset class.
Lee has consistently argued that Bitcoin is a superior store of value compared to fiat currencies or traditional safe-haven assets like U.S. Treasury. 
His firm has made multiple high-profile calls on crypto, often tying price action to broader macro trends and institutional flows.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46520495/strategy-buys-6220-btc-boosts-bitcoin-war-chest-to-607770">Strategy Buys 6,220 BTC, Boosts Bitcoin War Chest To 607,770</a>
Why It Matters: Discussing stablecoins, Lee said they represent the "ChatGPT moment" for crypto.
He noted strong demand from both consumers and businesses, citing activity from JPMorgan and Citi entering the stablecoin market.
For those looking to invest in the stablecoin boom, Lee suggested Ethereum remains the best proxy, stating that "over 30% of Ethereum's network fees come from stablecoins."
Ethereum's recent surge, up from $1,700 to over $3,600 in recent months, was also addressed. 
Lee noted that Fundstrat's technical team sees $5,000 as a near-term target. 
Longer-term, he placed Ethereum's potential valuation between $10,000 and $20,000, especially if stablecoin adoption continues to grow exponentially.
While acknowledging market volatility, Lee encouraged investors to focus on structural growth and fundamentals. 
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46516891/the-ether-machine-raises-1-5-billion-for-eth-investments">&#8216;The Ether Machine&#8217; Raises $1.5 Billion For ETH Investments</a></li>
</ul>
Image: Shutterstock

Is $1M Bitcoin Realistic? Tom Lee Says It May Be Closer Than You Think

A federal appeals court has sided with Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) in a long-running patent dispute, reversing a jury's finding that the company induced infringement of a Colibri Heart Valve LLC patent related to the implantation of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">artificial heart valves</a>.
At the heart of the case was Colibri's U.S. Patent No. 8,900,294, which outlines a method allowing surgeons to partially deploy and then recapture an artificial heart valve during implantation if the initial positioning appears off.
This technique gives surgeons a "do-over" opportunity to adjust placement before full deployment.
Thomson Reuters published a <a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/zjvqowykqvx/MEDTRONIC%20PATENT%20LAWSUIT%20APPEAL%20fedcir.pdf" rel="noreferrer noopener">copy</a> of the lawsuit online Monday.
Colibri alleged Medtronic encouraged surgeons to perform this method using its CoreValve products, thus infringing the patent under inducement rules in U.S. patent law.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46374572/medtronic-stock-is-climbing-friday-whats-going-on" target="_blank" rel="noreferrer noopener">Medtronic Stock Is Climbing Friday: What&#8217;s Going On?</a>
Initially, the patent application included two methods of partial deployment: pushing the valve from an outer sheath and retracting the sheath to expose the valve.
However, during patent prosecution, the U.S. Patent and Trademark Office rejected the retraction-based claim for lack of written description, leading Colibri to cancel it. The final patent only included claims directed to the push-based method.
At trial, Medtronic argued its devices used the retraction approach, not the push-based method claimed in the patent.
Colibri, abandoning a literal infringement claim, relied on the doctrine of equivalents—a legal principle that allows courts to find infringement even if the accused method is not identical to the one claimed, so long as it performs substantially the same function in substantially the same way.
A jury sided with Colibri, awarding over $106 million in damages and rejecting Medtronic's arguments, including its challenge that prosecution history estoppel barred Colibri's equivalents claim.
Prosecution history estoppel prevents a patent owner from recapturing through litigation what it gave up during the patenting process.
On appeal, however, the U.S. Court of Appeals for the Federal Circuit reversed. The panel ruled that Colibri's cancellation of the retraction-based claim and its acknowledgement of the overlap with the remaining push-based claim triggered prosecution history estoppel.
This barred Colibri from using the doctrine of equivalents to argue that Medtronic's retraction-based method was infringing.
With that determination, the court concluded there was no infringement as a matter of law, reversing the district court's judgment and vacating the $106 million verdict.
In June, Medtronic and its subsidiary, Given Imaging Inc., issued two letters to affected customers recommending that certain Bravo CF Capsule Delivery Devices be removed from <a href="https://www.benzinga.com/markets/large-cap/25/06/46102914/fda-sounds-alarm-after-33-injuries-tied-to-medtronic-device-malfunction" target="_blank" rel="noreferrer noopener">use and sold</a>.
Medtronic stated that the capsule may not attach to the patient&#8217;s esophagus or detach from the delivery device as intended due to a misapplication of the adhesive during manufacturing the Bravo CF capsule delivery device.
Medtronic&#8217;s cardiovascular segment revenue reached $3.34 billion, up 6.6% year-over-year in the fourth quarter of 2025, and increased 7.8% <a href="https://www.benzinga.com/25/05/45540768/medtronic-beats-q4-forecasts-hikes-dividend-plans-diabetes-spinoff" target="_blank" rel="noreferrer noopener">organically</a>.
Price Action: MDT stock is up 0.78% at $90.31 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/previews/25/07/46522985/coca-cola-q2-preview-will-warren-buffett-favorite-acknowledge-donald-trumps-sugar-push" target="_blank" rel="noreferrer noopener">Coca-Cola Q2 Preview: Will Warren Buffett Favorite Acknowledge Donald Trump&#8217;s Sugar Push?</a></li>
</ul>
Image: Shutterstock

Legal

Court Nixes Jury Award Over Medtronic's Heart Valve Infringement Claim

President Donald Trump has a history with <a href="https://www.benzinga.com/general/sports/21/06/21435064/the-history-of-usfl-nfl-stars-and-donald-trump-whats-next-with-2022-rebirth">sports team ownership</a>. With his latest comments about the names of National Football League and <a href="https://www.benzinga.com/topic/mlb">Major League Baseball</a> franchises making the rounds, here's a look back at how the president almost owned the very MLB team he's criticizing.
What Happened: Trump took to his Truth Social platform over the weekend to criticize the name changes made by several professional sports teams that were once named after Indians.
"The Washington ‘Whatever's' should IMMEDIATELY change their name back to the Washington Redskins Football Team," Trump said. "Likewise, the Cleveland Indians, one of the six original baseball teams, with a storied past."
In his first <a href="https://x.com/TrumpTruthOnX/status/1946939500346900737">post</a>, Trump said that the "great Indian people" want to see these team names changed back.
"Times are different now than they were three or four years ago. We are a Country of passion and common sense."
In a second <a href="https://x.com/TrumpTruthOnX/status/1947018752618594581">post</a>, Trump said his original message has blown up in a positive way and he went as far as saying that he might put restrictions on the NFL's Commanders if they don't change their name back.
"I may put a restriction on them that if they don't change the name back to the original ‘Washington Redskins,' and get rid of the ridiculous moniker, ‘Washington Commanders,' I won't make a deal for them to build a stadium in Washington."
Trump said Cleveland should do the same and change their name back to the Indians.
"Make Indians Great Again (MIGA)!"
Read Also: <a href="https://www.benzinga.com/news/25/02/43581549/billionaire-sports-owners-could-lose-tax-benefits-under-trumps-new-proposal">Billionaire Sports Owners Could Lose Tax Benefits Under Trump&#8217;s New Proposal</a>
Loyalty to Cleveland Indians Name, But Not The City: Trump attacking the Cleveland Indians name and team ownership has brought a story involving the team and Trump back to light.
While Trump is preaching loyalty to the team's past name and the Indians name and mascot, the president once bid on buying the MLB team, but couldn't back the team with his loyalty.
Trump offered $13 million to buy the Indians in February 1983, as <a href="https://www.sportingnews.com/us/mlb/news/donald-trump-indians-presidential-campaign-gop/1ggpmth8ig5nv1l4clvzm4ewoi">reported </a>by the Sporting News. Trump's lawyer at the time sent a letter to then Indians president Gabe Paul. &nbsp;
"I am authorized to offer Thirteen Million dollars for same free from debt and subject to usual review and acceptance of all contracts in effect," the letter reads.
Trump also reportedly raised his offer later that year to $34 million.
The future president's offers to buy the Indians were rejected. One of the main reasons why was that Trump would not commit to keeping the Indians in the city of Cleveland for more than three years.
Reports say Tampa was mentioned as one of the locations for Trump to move the team to if he was successful in his bid.
The team later sold for $35 million to the Jacobs brothers.
Trump's bid came after the 1982 MLB season when the Indians went 70-92 and hadn't made the MLB Playoffs since 1954. The bid also came before the city of Tampa eventually got an MLB franchise with the Tampa Bay Devil Rays, now known as the Tampa Bay Rays, beginning play in the 1998 season.
Why It's Important: The Indians are valued at $1.4 billion today, ranking 25th among MLB franchises, according to <a href="https://www.forbes.com/sites/justinteitelbaum/2025/03/26/baseballs-most-valuable-teams-2025/">Forbes</a>.
While the team struggled in the decades before Trump's bid, the team has made the MLB Playoffs in six of the last nine seasons. The franchise won World Series titles in 1920 and 1948 and lost in the World Series in 1954, 1995, 1997 and 2016.
The Indians made three World Series appearances since Trump's bid.
The team seems content with keeping their name.
"We've gotten the opportunity to build the brand as the Guardians over the last four years and are excited about the future," Cleveland Guardians' president of baseball operations Chris Antonetti told <a href="https://www.usatoday.com/story/sports/mlb/guardians/2025/07/20/cleveland-guardians-response-trump-indians-commanders-name/85300777007/">reporters </a>Sunday.
Antonetti said changing the name back to Indians is not something the team is tracking or has been paying attention to.
When it comes to the Cleveland MLB franchise, it looks like Trump will be unsuccessful at buying the team and unsuccessful at getting the team to change its name back.
As with his potential NFL team ownership, while looking at the potential that Trump owned an MLB team today, fans and critics of the current president can&#8217;t help but question if things would look different today. 
If Trump owned a professional sports team, would he have entered politics and become president?
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/sports/24/11/42101566/trump-dance-takes-over-sports-celebrations-move-over-griddy-gronk-spike-athletes-are-paying-tribute-or-poking-fun-at-president-elect">Trump Dance Takes Over Sports Celebrations: Move Over Griddy, Gronk Spike, Athletes Are Paying Tribute (Or Poking Fun) At President-Elect</a></li>
</ul>
Photo: Shutterstock

Entertainment

Politics

Sports

Trump Says 'Make Indians Great Again': 42 Years Ago, He Tried To Buy And Move The Cleveland Indians

Forestar Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOR#NYSE">FOR</a>) will release its quarterly earnings report on Tuesday, 2025-07-22. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Forestar Group to report an earnings per share (EPS) of $0.77.
The market awaits Forestar Group's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company missed EPS by $0.09, leading to a 0.0% drop in the share price the following trading session.
Here's a look at Forestar Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.73</td>
<td>0.70</td>
<td>1.31</td>
<td>0.88</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.64</td>
<td>0.32</td>
<td>1.51</td>
<td>0.76</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753120971_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Forestar Group were trading at $21.84 as of July 18. Over the last 52-week period, shares are down 30.17%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Insights on Forestar Group</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Forestar Group.
Analysts have provided Forestar Group with 1 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $30.0, suggesting a potential 37.36% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of and Forestar Group, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<h3>Peer Analysis Summary</h3>
In the peer analysis summary, key metrics for and Forestar Group are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forestar Group</td>
<td>Outperform</td>
<td>5.15%</td>
<td>$79.20M</td>
<td>1.94%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Forestar Group ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is in the middle for Return on Equity.
<h3>About Forestar Group</h3>
Forestar Group Inc is a residential lot development company with operations across the United States. The core business segment for the company is real estate which generates all of it's revenues. The firm fundamentally acquires entitled real estate and develops it into finished residential lots for sale to homebuilders with a strategic focus on asset turns and efficiency. Single-family residential communities account for the majority of their real estate projects. The company utilizes a lower-risk business model mainly by investing in short duration, phased development projects.
<h3>Forestar Group: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Forestar Group's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 5.15%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.
Net Margin: Forestar Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.0% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Forestar Group's ROE excels beyond industry benchmarks, reaching 1.94%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Forestar Group's ROA excels beyond industry benchmarks, reaching 1.05%. This signifies efficient management of assets and strong financial health.
Debt Management: Forestar Group's debt-to-equity ratio is below the industry average. With a ratio of 0.54, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/FOR/earnings">To track all earnings releases for Forestar Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Insights Ahead: Forestar Group's Quarterly Earnings

Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-07-22. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Range Resources will report an earnings per share (EPS) of $0.65.
The announcement from Range Resources is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.05, leading to a 2.28% increase in the share price on the subsequent day.
Here's a look at Range Resources's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.91</td>
<td>0.60</td>
<td>0.38</td>
<td>0.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.96</td>
<td>0.68</td>
<td>0.48</td>
<td>0.46</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>3.0%</td>
<td>4.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753120962_0.png" alt="eps graph" />
<h3>Performance of Range Resources Shares</h3>
Shares of Range Resources were trading at $38.28 as of July 18. Over the last 52-week period, shares are up 8.88%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Views on Range Resources</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Range Resources.
Range Resources has received a total of 10 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $41.5, the consensus suggests a potential 8.41% upside.
<h3>Analyzing Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Permian Resources, Ovintiv and APA, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Permian Resources, with an average 1-year price target of $18.1, suggesting a potential 52.72% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Ovintiv, with an average 1-year price target of $50.71, suggesting a potential 32.47% upside.</li>
<li>Analysts currently favor an Neutral trajectory for APA, with an average 1-year price target of $21.12, suggesting a potential 44.83% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary presents essential metrics for Permian Resources, Ovintiv and APA, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Range Resources</td>
<td>Neutral</td>
<td>42.04%</td>
<td>$366.09M</td>
<td>2.46%</td>
</tr>
<tr>
<td>Permian Resources</td>
<td>Buy</td>
<td>10.74%</td>
<td>$675.97M</td>
<td>3.57%</td>
</tr>
<tr>
<td>Ovintiv</td>
<td>Outperform</td>
<td>1.06%</td>
<td>$1.34B</td>
<td>-1.56%</td>
</tr>
<tr>
<td>APA</td>
<td>Neutral</td>
<td>35.11%</td>
<td>$1.01B</td>
<td>6.48%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Range Resources ranks in the middle for consensus rating among its peers. It ranks at the bottom for revenue growth. In terms of gross profit, it is at the bottom among its peers. For return on equity, Range Resources is at the bottom compared to its peers.
<h3>About Range Resources</h3>
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.18 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
<h3>Unraveling the Financial Story of Range Resources</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Range Resources's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 42.04%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Range Resources's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 11.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Range Resources's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.46%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.31%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.46.
<a href="https://www.benzinga.com/quote/RRC/earnings">To track all earnings releases for Range Resources visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Range Resources's Future Earnings

Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-07-22. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Invesco will report an earnings per share (EPS) of $0.39.
The market awaits Invesco's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.06, which was followed by a 0.15% increase in the share price the next day.
Here's a look at Invesco's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.38</td>
<td>0.47</td>
<td>0.43</td>
<td>0.40</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.44</td>
<td>0.52</td>
<td>0.44</td>
<td>0.43</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-2.0%</td>
<td>-3.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753120954_0.png" alt="eps graph" />
<h3>Market Performance of Invesco's Stock</h3>
Shares of Invesco were trading at $19.92 as of July 18. Over the last 52-week period, shares are up 19.43%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Invesco</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Invesco.
With 11 analyst ratings, Invesco has a consensus rating of Neutral. The average one-year price target is $16.75, indicating a potential 15.91% downside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of SEI Investments, Janus Henderson Group and Hamilton Lane, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for SEI Investments, with an average 1-year price target of $91.56, suggesting a potential 359.64% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Janus Henderson Group, with an average 1-year price target of $39.0, suggesting a potential 95.78% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Hamilton Lane, with an average 1-year price target of $162.2, suggesting a potential 714.26% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for SEI Investments, Janus Henderson Group and Hamilton Lane, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invesco</td>
<td>Neutral</td>
<td>3.65%</td>
<td>$555.60M</td>
<td>1.61%</td>
</tr>
<tr>
<td>SEI Investments</td>
<td>Outperform</td>
<td>7.77%</td>
<td>$303.95M</td>
<td>6.72%</td>
</tr>
<tr>
<td>Janus Henderson Group</td>
<td>Neutral</td>
<td>12.63%</td>
<td>$423.80M</td>
<td>2.55%</td>
</tr>
<tr>
<td>Hamilton Lane</td>
<td>Neutral</td>
<td>12.06%</td>
<td>$133.25M</td>
<td>7.39%</td>
</tr>
</tbody>
</table>

Key Takeaway:
In terms of consensus rating, Invesco is rated neutral, similar to two peers. For revenue growth, Invesco ranks lowest among peers. In gross profit, Invesco is at the top compared to peers. When it comes to return on equity, Invesco is at the bottom among its peers.
<h3>Delving into Invesco's Background</h3>
Invesco provides investment-management services to retail (67% of managed assets) and institutional (33%) clients. At the end of April 2025, the firm had $1.840 trillion in assets under management spread among its equity (57% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (11%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).
<h3>Financial Insights: Invesco</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Invesco showcased positive performance, achieving a revenue growth rate of 3.65% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 11.19%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Invesco's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.61%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Invesco's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.62%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Invesco's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/IVZ/earnings">To track all earnings releases for Invesco visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Invesco

Press Releases

Palladyne AI Selected for Participation at USSOCOM TE25-2: Collaborative Autonomy Integration Event

Palladyne AI Announces Employee Equity Awards

Palladyne AI and Red Cat Announce Successful Completion of Cross-Platform Collaborative Drone Flight

Palladyne AI to Participate in Upcoming Investor Conference

How the Industry of Drones is Evolving Rapidly with New Trends and Technologies Emerging Regularly

Palladyne AI Corp. to Join Russell 3000® and Russell 2000® Index

Palladyne IQ AI Software Platform Named the Sole Finalist from the Robotics and Automation Category for an Annual National Center for Manufacturing Sciences Technology Competition

Palladyne AI Corp. Receives Additional Funding Via U.S. Air Force Contract

Mobilicom and Palladyne AI Partner to Deliver Cybersecure Autonomy for Drones, Industrial Robots and Other Unmanned Systems

Small Cap

Opinion

Latest Drone Production Initiatives Big Boon for Manufacturers Focused on Commercial Uses and Applications

Comments

Palladyne AI

Actualités

Dernières nouvelles pour Palladyne AI (NASDAQ:PDYN) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL